SCM
INSY

Stonepine Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Stonepine Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,000
Closed -$32K – 25
2016
Q1 		$32K Buy
+2,000
New +$38K 0.04% 18

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stonepine Capital Management's INSY Position: Q2 2016 in Review

Stonepine Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 2,000 shares — an estimated $32K sold.

Stonepine Capital Management first reported a position in INSY in Q1 2016 and held it in 1 quarter. The position peaked at $32K in Q1 2016. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

  • Stonepine Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Stonepine Capital Management sold 2,000 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $32K.
  • Stonepine Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • Stonepine Capital Management's Insys Therapeutics, Inc. position peaked at $32K in Q1 2016.
  • 124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.